BioXcel Therapeutics Total Liabilities

As of the most recent data (June 2026), BTAI shows a total liabilities of $140M. That compares with $130M in the prior-year period — up 8.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BTAI's total liabilities is now $140M (was $130M) — a 8.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BioXcel Therapeutics is outperforming or lagging.

Tracking BTAI's total liabilities over time shows whether BioXcel Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $140M That compares with $130M in the prior-year period — up 8.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has BioXcel Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $140M) with ownership activity and broader fundamentals.

BioXcel Therapeutics's total liabilities is $140M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.